Efficacy and Tolerability of Brivaracetam in Chinese Population: Focus on Switch From Levetiracetam

Am J Ther. 2023 Nov-Dec;30(6):e565-e570. doi: 10.1097/MJT.0000000000001501. Epub 2022 May 23.

Affiliations

¹ Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
² Division of Neurology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong.
³ Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong.
⁴ Department of Medicine, Tseung Kwan O Hospital, Hong Kong.
⁵ Department of Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong.

PMID: 35604724
DOI: 10.1097/MJT.0000000000001501

No abstract available

Publication types

Letter

MeSH terms

Anticonvulsants* / therapeutic use
Drug Substitution*
East Asian People
Humans
Levetiracetam / therapeutic use
Pyrrolidinones* / therapeutic use
Treatment Outcome

Substances

Anticonvulsants
brivaracetam
Levetiracetam
Pyrrolidinones